Safety of combined oval contraceptive pills [15]

Lancet

Volumn 347, Issue 9000, 1996, Pages 546-549

  Cramer, D W ^a   Poulter, N R ^a   Farley, T M M ^a   Chang, C L ^a   Marmot, M G ^a   Meirik, O ^a   De Lignieres, B ^a   Plu Bureau, G ^a   Amiral, J ^a   Guize, L ^a   Scarabin, P Y ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; GESTAGEN; GESTODENE; ORAL CONTRACEPTIVE AGENT; PREGNANE DERIVATIVE; PROGESTERONE DERIVATIVE;

DRUG SAFETY; LETTER; LUNG EMBOLISM; ORAL CONTRACEPTION; PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBOPHLEBITIS; VEIN THROMBOSIS; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; NOTE;

CONTRACEPTIVES, ORAL, COMBINED; DESOGESTREL; FEMALE; HUMANS; NORPREGNENES; PROGESTERONE CONGENERS; THROMBOEMBOLISM; THROMBOPHLEBITIS;

EID: 0030599796     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)91181-2     Document Type: Letter

References (22)

1. Tmm Farley O. Meirik Cl Chang Mg Marmot Nr Poulter Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease Lancet 346 1995 1582 1588
2. H. Jick Ss Jick V. Gurewich Mw Myers C. Vasilakis Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components Lancet 346 1995 1589 1593
3. Kwm Bloemenkamp Fr Rosendaal Fm Helmerhost Hr Buller Jp Vandenbroucke Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen Lancet 346 1995 1593 1596
4. Rdt Farmer Td Preston The risk of thromboembolism associated with low estrogen and contraceptives J Obstet Gynecol 15 1995 195 200
5. Jp Vandenbroucke T. Koster E. Briet Ph Reitsma Rm Bertina Fr Rosendaal Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation Lancet 344 1994 1453 1457
6. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study Lancet 346 1995 1575 1582
7. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease Lancet 346 1995 1582 1588
8. E. Johannisson Safety of modern oral contraceptives Lancet 347 1996 258
9. R. Farmer Safety of modern oral contraceptives Lancet 347 1996 259
10. M. Rawlins Combined oral contraceptives and thromboembolism BMJ 311 1995 1232
11. Kwm Bloemenkamp Fr Rosendaal Fm Helmerhorst Hr Buller Jp Vandenbroucke Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen Lancet 346 1995 83 87
12. Wo Spitzer Ma Lewis Laj Heinemann Third generation oral contraceptives and risk of venous thrombosis, an international case-control study BMJ 312 1996 83 88
13. K. MacRae C. Kay Third generation oral contraceptive pills BMJ 311 1995 1112
14. R. Farmer Safety of modern oral contraceptives Lancet 347 1996 259
15. N. Weiss Third-generation oral contraceptives: how risky Lancet 346 1995 1570
16. H. Jick Ss Jick V. Gurewich Mw Myers C. Vasilakis Risk of idiopathic cardiovascular death and nonfatal thromboembolism in women using oral contraceptives with differing progestagen components Lancet 346 1995 1589 1593
17. Rdt Farmer Td Preston The risk of thromboembolism associated with low oestrogen and contraceptives J Obstet Gynecol 15 1995 195 200
18. E. Johannisson Safety of modern oral contraception Lancet 347 1996 258
19. R. Kauppinen-Makelin T. Kuusi O. Ylikorkala M. Tikkanen Contraceptives containing desogestrel or levonorgestrel have different effects on serum lipoproteins and post-heparin plasma lipase activities Clin Endocrinol 36 1992 203 209
20. B. de Lignieres The case for a non plasma lipoprotein etiology of reduced vascular risk in estrogen replacement therapy Curr Opin Obstet Gynecol 5 1993 389 395
21. Ma Lewis Wo Spitzer La Heinemann Third generation oral contraceptives and risk of myocardial infarction: an international case-control study BMJ 312 1996 88 90
22. Py Scarabin G. Plu-Bureau D. Zitoun L. Bara L. Guize Mm Samama Changes in haemostatic variables induced by oral contraceptives containing 50 μg or 30 μg ostrogen: absence of dose effect on PAI-1 activity Thromb Haemost 74 1995 928 932